SG10201609644UA - Glucokinase activator compositions for the treatment of diabetes - Google Patents

Glucokinase activator compositions for the treatment of diabetes

Info

Publication number
SG10201609644UA
SG10201609644UA SG10201609644UA SG10201609644UA SG10201609644UA SG 10201609644U A SG10201609644U A SG 10201609644UA SG 10201609644U A SG10201609644U A SG 10201609644UA SG 10201609644U A SG10201609644U A SG 10201609644UA SG 10201609644U A SG10201609644U A SG 10201609644UA
Authority
SG
Singapore
Prior art keywords
diabetes
treatment
glucokinase activator
activator compositions
compositions
Prior art date
Application number
SG10201609644UA
Other languages
English (en)
Inventor
Lopez Maria Carmen Valcarce
Tung Fong
Original Assignee
Vtv Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vtv Therapeutics Llc filed Critical Vtv Therapeutics Llc
Publication of SG10201609644UA publication Critical patent/SG10201609644UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG10201609644UA 2012-05-17 2013-05-15 Glucokinase activator compositions for the treatment of diabetes SG10201609644UA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261648110P 2012-05-17 2012-05-17

Publications (1)

Publication Number Publication Date
SG10201609644UA true SG10201609644UA (en) 2017-01-27

Family

ID=48576527

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201406987UA SG11201406987UA (en) 2012-05-17 2013-05-15 Glucokinase activator compositions for the treatment of diabetes
SG10201609644UA SG10201609644UA (en) 2012-05-17 2013-05-15 Glucokinase activator compositions for the treatment of diabetes

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201406987UA SG11201406987UA (en) 2012-05-17 2013-05-15 Glucokinase activator compositions for the treatment of diabetes

Country Status (16)

Country Link
US (3) US10004782B2 (enExample)
EP (1) EP2849776B1 (enExample)
JP (1) JP6234443B2 (enExample)
KR (2) KR102371364B1 (enExample)
CN (2) CN118453592A (enExample)
AU (2) AU2013262895A1 (enExample)
BR (1) BR112014028622A2 (enExample)
CA (1) CA2872021C (enExample)
EA (1) EA201492109A1 (enExample)
ES (1) ES2878001T3 (enExample)
HK (1) HK1202458A1 (enExample)
IL (1) IL235484A0 (enExample)
IN (1) IN2014DN09554A (enExample)
MX (1) MX360304B (enExample)
SG (2) SG11201406987UA (enExample)
WO (1) WO2013173417A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101878252B1 (ko) 2010-05-26 2018-07-13 브이티브이 테라퓨틱스 엘엘씨 글루코키나아제 활성화제와 병용되는 메트포르민의 용도, 및 메트포르민과 글루코키나아제 활성화제를 포함하는 조성물
CN118453592A (zh) * 2012-05-17 2024-08-09 Vtv治疗有限责任公司 用于治疗糖尿病的葡萄糖激酶活化剂组合物
KR102408480B1 (ko) 2018-05-30 2022-06-10 이삼구 당뇨질환의 치료용 조성물
CN114209694A (zh) * 2018-05-31 2022-03-22 华领医药技术（上海）有限公司 含有葡萄糖激酶激活剂和ppar受体激活剂的药物组合及其制备方法和用途
WO2019241089A1 (en) 2018-06-12 2019-12-19 Vtv Therapeutics Llc Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
US11872221B2 (en) 2020-01-31 2024-01-16 Hua Medicine (Shanghai) Ltd. Treating untreated or treatment-resistant diabetes with glucokinase activator
CA3169432A1 (en) * 2020-01-31 2021-08-05 Hua Medicine (Shanghai) Ltd. Treating treatment-resistant diabetes with glucokinase activator
WO2021167840A1 (en) 2020-02-18 2021-08-26 Vtv Therapeutics Llc Sulfoxide and sulfone glucokinase activators and methods of use thereof
US11857536B2 (en) 2020-06-04 2024-01-02 Hua Medicine (Shanghai) Ltd. Glucokinase activator for treating diabetes with renal impairment
CA3185834A1 (en) * 2020-06-04 2021-12-09 Hua Medicine (Shanghai) Ltd. Glucokinase activator for treating diabetes with hepatic impairment
AU2020451588A1 (en) * 2020-06-04 2023-01-19 Hua Medicine (Shanghai) Ltd. Glucokinase activator for treating diabetes with renal impairment
CA3181722A1 (en) * 2020-06-08 2021-12-16 Jing TENG Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof
AU2021289591A1 (en) * 2020-06-08 2023-01-19 Vtv Therapeutics Llc Crystalline forms of {2-[3-cyclohexyl-3-(trans-4-propoxy- cyclohexyl)-ureido]-thiazol-5-ylsulfanyl} -acetic acid and and uses thereof
CN115350268B (zh) * 2022-08-24 2025-02-11 深圳青澜生物技术有限公司 一种用于治疗糖尿病的制剂、微针及其制备工艺

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT323195B (de) 1973-03-16 1975-06-25 Hurka Wilhelm Verfahren zur herstellung neuer salze von biguaniden
FR2243684B1 (enExample) 1973-09-19 1977-01-28 Semb
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US6794412B1 (en) * 1999-03-11 2004-09-21 Bristol-Myers Squibb Pharma Company Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
DK1133312T3 (da) * 1999-06-21 2008-01-02 Lilly Co Eli Synergistisk anvendelse af thiazolidindioner med glucagonlignende peptid-1 og agonister deraf til behandling af ikke-insulinafhængig diabetes
US6294546B1 (en) * 1999-08-30 2001-09-25 The Broad Of Trustees Of The Leland Stanford Junior University Uses of diterpenoid triepoxides as an anti-proliferative agent
US6608038B2 (en) * 2000-03-15 2003-08-19 Novartis Ag Methods and compositions for treatment of diabetes and related conditions via gene therapy
EP1531815B1 (en) 2002-06-27 2014-09-24 Novo Nordisk A/S Glucokinase activators
WO2004076420A1 (ja) 2003-02-26 2004-09-10 Banyu Pharmaceutical Co., Ltd. ヘテロアリールカルバモイルベンゼン誘導体
WO2005006614A1 (ja) 2003-07-14 2005-01-20 Sony Corporation 情報提供方法
WO2005023766A1 (en) 2003-09-11 2005-03-17 Biocon Limited Salt of atorvastatin with metformin
DK1723128T3 (da) 2004-01-06 2013-02-18 Novo Nordisk As Heteroarylurinstoffer og deres anvendelse som glucokinaseaktivatorer
CN1910166B (zh) * 2004-01-06 2012-01-04 诺和诺德公司 杂芳基脲及其作为葡糖激酶活化剂的用途
JP2008502658A (ja) * 2004-06-17 2008-01-31 ノボ　ノルディスク　アクティーゼルスカブ 肝臓選択的グルコキナーゼ活性化因子の使用
WO2006110809A2 (en) 2005-04-12 2006-10-19 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
US20100028439A1 (en) 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
ATE547396T1 (de) 2005-07-08 2012-03-15 Novo Nordisk As Dicycloalkylcarbamoyl-harnstoffe als glucokinase- aktivatoren
WO2007006760A1 (en) 2005-07-08 2007-01-18 Novo Nordisk A/S Dicycloalkyl urea glucokinase activators
CN101258137A (zh) * 2005-07-08 2008-09-03 诺沃-诺迪斯克有限公司 双环烷基脲葡糖激酶活化剂
RU2443691C2 (ru) 2005-07-14 2012-02-27 Транстех Фарма, Инк. Мочевинные активаторы глюкокиназы
US8163779B2 (en) 2006-12-20 2012-04-24 Takeda San Diego, Inc. Glucokinase activators
JP2010515701A (ja) 2007-01-09 2010-05-13 ノボ・ノルデイスク・エー／エス ウレアグルコキナーゼアクチベーター
US8563730B2 (en) 2008-05-16 2013-10-22 Takeda San Diego, Inc. Pyrazole and fused pyrazole glucokinase activators
WO2010010760A1 (ja) 2008-07-22 2010-01-28 株式会社クレハ 末端ハロゲン基含量が低減されたポリアリーレンスルフィドの製造方法
WO2010107610A1 (en) 2009-03-17 2010-09-23 Merck Sharp & Dohme Corp. Method for treatment of diabetes and related conditions with combination therapy and compositions containing such compounds
SG2014012462A (en) 2009-04-16 2014-05-29 Taisho Pharmaceutical Co Ltd Pharmaceutical compositions
WO2011025270A2 (ko) 2009-08-25 2011-03-03 한올바이오파마주식회사 메트포르민 카페익산염, 그의 제조방법, 그를 포함하는 약학조성물 및 그를 포함하는 복합제제
KR101878252B1 (ko) * 2010-05-26 2018-07-13 브이티브이 테라퓨틱스 엘엘씨 글루코키나아제 활성화제와 병용되는 메트포르민의 용도, 및 메트포르민과 글루코키나아제 활성화제를 포함하는 조성물
EP2392575A1 (en) * 2010-06-04 2011-12-07 LEK Pharmaceuticals d.d. A novel synthetic approach to ß-aminobutyryl substituted compounds
CN118453592A (zh) 2012-05-17 2024-08-09 Vtv治疗有限责任公司 用于治疗糖尿病的葡萄糖激酶活化剂组合物
AU2014226290B2 (en) 2013-03-04 2018-11-15 Vtv Therapeutics Llc Stable glucokinase activator compositions
WO2014137799A1 (en) 2013-03-04 2014-09-12 Transtech Pharma, Llc Solid compositions comprising a glucokinase activator and methods of making and using the same

Also Published As

Publication number Publication date
US20140066372A1 (en) 2014-03-06
HK1202458A1 (en) 2015-10-02
KR20150013838A (ko) 2015-02-05
IL235484A0 (en) 2014-12-31
US10980861B2 (en) 2021-04-20
EP2849776B1 (en) 2021-04-21
ES2878001T3 (es) 2021-11-18
US10588943B2 (en) 2020-03-17
CN118453592A (zh) 2024-08-09
AU2013262895A1 (en) 2014-11-13
CA2872021C (en) 2022-08-16
JP6234443B2 (ja) 2017-11-22
KR20210027547A (ko) 2021-03-10
CN104349790A (zh) 2015-02-11
US20180311314A1 (en) 2018-11-01
IN2014DN09554A (enExample) 2015-07-17
MX2014013105A (es) 2015-04-08
CA2872021A1 (en) 2013-11-21
WO2013173417A2 (en) 2013-11-21
AU2017203835B2 (en) 2018-11-22
US10004782B2 (en) 2018-06-26
KR102371364B1 (ko) 2022-03-07
SG11201406987UA (en) 2014-12-30
MX360304B (es) 2018-10-29
WO2013173417A3 (en) 2014-02-20
EP2849776A2 (en) 2015-03-25
AU2017203835A1 (en) 2017-06-22
BR112014028622A2 (pt) 2017-06-27
EA201492109A1 (ru) 2015-07-30
JP2015517525A (ja) 2015-06-22
US20200138909A1 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
IL235484A0 (en) Glucokinase-activating preparations for the treatment of diabetes
GB2511713B (en) Compositions for the treatment of bone fragility
ZA201403795B (en) Formulations for the treatment of diabetes
LT2916860T (lt) Diabeto gydymui skirta kompozicija, apimanti oksintomodulino analogą
IL237275A0 (en) Compounds for the treatment of paramoxovirus viral infections
IL231836A0 (en) The vehicle for treating the siege
PL2922893T3 (pl) Kompozycje utwardzane wilgocią, sposób ich wytwarzania i ich zastosowania
ZA201500229B (en) Combinations of modalities for the treatment of diabetes
EP2867239A4 (en) OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES
SG11201509782TA (en) Compositions and methods for the treatment of diabetes and pre-diabetes
IL240735A0 (en) Stable glucokinase activator compounds
HRP20181761T1 (hr) Novi pripravak alfentanila za liječenje akutne boli
ZA201408065B (en) Compositions and methods for the treatment of diabetes
HUE040421T2 (hu) Készítmények és eljárások 1-es típusú cukorbetegség kezelésére
HUP1200552A2 (en) Pharmaceutical compositions for the treatment of high blood pressure
ZA201409502B (en) Composition for treatment of warts
IL232294A0 (en) Preparations for the treatment of diabetes
HK1201731B (en) Compositions for the treatment of bone fragility
SI2812351T1 (sl) Farmacevtski sestavek za zdravljenje multiple skleroze
HUP1100245A2 (en) Pharmaceutical composition for the treatment of wounds